[144] Alnylam Pharmaceuticals, Inc. SEC Filing
Alnylam Pharmaceuticals (ALNY) notice reports a proposed sale of 18,000 shares of common stock through UBS Financial Services on the NASDAQ, with an aggregate market value of $8,300,070.00 and 131,079,015 shares outstanding. The securities were acquired and are proposed to be sold on 09/09/2025 via exercise of stock options from the issuer, with cash payment recorded. The filer reports no securities sold in the past three months. The form includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption if applicable.
Alnylam Pharmaceuticals (ALNY) segnala la proposta di vendita di 18.000 azioni ordinarie tramite UBS Financial Services sul NASDAQ, per un valore di mercato complessivo di $8.300.070,00 e con 131.079.015 azioni in circolazione. Le azioni sono state acquisite e si prevede la vendita in data 09/09/2025 mediante l'esercizio di opzioni su azioni emesse dalla societ脿, con pagamento in contanti. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi. Il modulo riporta la dichiarazione standard secondo cui il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate e cita l'adozione di un piano ai sensi della Regola 10b5-1, se applicabile.
Alnylam Pharmaceuticals (ALNY) comunica la propuesta de venta de 18.000 acciones ordinarias a trav茅s de UBS Financial Services en el NASDAQ, con un valor de mercado agregado de $8.300.070,00 y 131.079.015 acciones en circulaci贸n. Los valores fueron adquiridos y se propone venderlos el 09/09/2025 mediante el ejercicio de opciones sobre acciones emitidas por la compa帽铆a, con pago en efectivo. El presentador informa que no ha vendido valores en los 煤ltimos tres meses. El formulario incluye la declaraci贸n est谩ndar de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada y hace referencia a la adopci贸n de un plan conforme a la Regla 10b5-1 cuando corresponda.
Alnylam Pharmaceuticals (ALNY)電� NASDAQ鞐愳劀 UBS Financial Services毳� 韱淀暣 18,000欤检潣 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 瓿奠頄堨溂氅�, 齑� 鞁滉皜鞎� $8,300,070.00鞚搓碃 氚滍枆欤检嫕靾� 131,079,015欤检瀰雼堧嫟. 頃措嫻 歃濌秾鞚� 旆摑霅橃棃瓿� 氚滍枆須岇偓鞚� 欤检嫕毵れ垬靹犿儩甓� 頄夓偓搿� 2025-09-09鞐� 毵り皝頃� 鞓堨爼鞚措┌, 瓴办牅電� 顺勱笀鞙茧 旮半霅橃棃鞀惦媹雼�. 鞝滌稖鞚胳潃 瓿缄卑 靹� 雼皠 毵る弰頃� 歃濌秾鞚� 鞐嗠嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞏戩嫕鞐愲姅 毵る弰鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 響滌 歆勳垹瓿�, 頃措嫻霅橂姅 瓴届毎 Rule 10b5-1 瓿勴殟 毂勴儩鞐� 雽�頃� 鞏戈笁鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Alnylam Pharmaceuticals (ALNY) signale la proposition de vente de 18 000 actions ordinaires par l'interm茅diaire d'UBS Financial Services sur le NASDAQ, pour une valeur de march茅 globale de 8 300 070,00 $ et 131 079 015 actions en circulation. Les titres ont 茅t茅 acquis et la vente est propos茅e le 09/09/2025 suite 脿 l'exercice d'options sur actions 茅mises par la soci茅t茅, avec paiement en 别蝉辫猫肠别蝉. Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois. Le formulaire contient la d茅claration standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables mat茅rielles non divulgu茅es et mentionne l'adoption d'un plan en vertu de la r猫gle 10b5-1, le cas 茅ch茅ant.
Alnylam Pharmaceuticals (ALNY) meldet den geplanten Verkauf von 18.000 Stammaktien 眉ber UBS Financial Services an der NASDAQ, mit einem gesamten Marktwert von $8.300.070,00 und 131.079.015 ausstehenden Aktien. Die Wertpapiere wurden erworben und sollen am 09.09.2025 durch Aus眉bung von Aktienoptionen des Emittenten verkauft werden, die Zahlung erfolgte in Bargeld. Der Einreicher berichtet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Das Formular enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind, und verweist gegebenenfalls auf die Annahme eines Rule鈥�10b5鈥�1鈥慞lans.
- Transaction executed through a major broker-dealer (UBS Financial Services)
- No securities sold in the past three months, as reported on the form
- Form includes seller's representation about absence of undisclosed material adverse information
- Aggregate market value is $8,300,070.00, representing a non-trivial cash amount proposed for sale
- Form lacks identification of the selling person's name or relationship in the provided extract, limiting context
Insights
TL;DR: Insider-originated sale notice for 18,000 shares worth $8.3M, executed via a major broker, appears routine and small relative to total shares outstanding.
The filing documents a single proposed sale of 18,000 common shares acquired and to be sold on the same date by exercise of stock options, with cash payment. Execution through UBS Financial Services suggests use of an established broker-dealer. The filing notes no prior sales in the last three months and includes the statutory representation about material nonpublic information. Based solely on the disclosed facts, this is a routine insider transaction notice without additional context on the seller's identity or any trading plan.
TL;DR: Form 144 records a compliance disclosure for a planned sale; it includes the required seller certification and Rule 10b5-1 mention.
The notice contains the standard attestations required by Rule 144, including the seller's representation regarding material information and an explicit field for Rule 10b5-1 plan adoption or instruction date. The form indicates acquisition via option exercise and immediate planned disposition, and it reports no aggregated recent sales by the filer. From a governance and disclosure perspective, the filing meets the procedural elements presented here; no governance issues or compliance exceptions are evident from the disclosed content.
Alnylam Pharmaceuticals (ALNY) segnala la proposta di vendita di 18.000 azioni ordinarie tramite UBS Financial Services sul NASDAQ, per un valore di mercato complessivo di $8.300.070,00 e con 131.079.015 azioni in circolazione. Le azioni sono state acquisite e si prevede la vendita in data 09/09/2025 mediante l'esercizio di opzioni su azioni emesse dalla societ脿, con pagamento in contanti. Il dichiarante segnala di non aver venduto titoli negli ultimi tre mesi. Il modulo riporta la dichiarazione standard secondo cui il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate e cita l'adozione di un piano ai sensi della Regola 10b5-1, se applicabile.
Alnylam Pharmaceuticals (ALNY) comunica la propuesta de venta de 18.000 acciones ordinarias a trav茅s de UBS Financial Services en el NASDAQ, con un valor de mercado agregado de $8.300.070,00 y 131.079.015 acciones en circulaci贸n. Los valores fueron adquiridos y se propone venderlos el 09/09/2025 mediante el ejercicio de opciones sobre acciones emitidas por la compa帽铆a, con pago en efectivo. El presentador informa que no ha vendido valores en los 煤ltimos tres meses. El formulario incluye la declaraci贸n est谩ndar de que el vendedor no tiene conocimiento de informaci贸n material adversa no divulgada y hace referencia a la adopci贸n de un plan conforme a la Regla 10b5-1 cuando corresponda.
Alnylam Pharmaceuticals (ALNY)電� NASDAQ鞐愳劀 UBS Financial Services毳� 韱淀暣 18,000欤检潣 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 瓿奠頄堨溂氅�, 齑� 鞁滉皜鞎� $8,300,070.00鞚搓碃 氚滍枆欤检嫕靾� 131,079,015欤检瀰雼堧嫟. 頃措嫻 歃濌秾鞚� 旆摑霅橃棃瓿� 氚滍枆須岇偓鞚� 欤检嫕毵れ垬靹犿儩甓� 頄夓偓搿� 2025-09-09鞐� 毵り皝頃� 鞓堨爼鞚措┌, 瓴办牅電� 顺勱笀鞙茧 旮半霅橃棃鞀惦媹雼�. 鞝滌稖鞚胳潃 瓿缄卑 靹� 雼皠 毵る弰頃� 歃濌秾鞚� 鞐嗠嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞏戩嫕鞐愲姅 毵る弰鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 響滌 歆勳垹瓿�, 頃措嫻霅橂姅 瓴届毎 Rule 10b5-1 瓿勴殟 毂勴儩鞐� 雽�頃� 鞏戈笁鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Alnylam Pharmaceuticals (ALNY) signale la proposition de vente de 18 000 actions ordinaires par l'interm茅diaire d'UBS Financial Services sur le NASDAQ, pour une valeur de march茅 globale de 8 300 070,00 $ et 131 079 015 actions en circulation. Les titres ont 茅t茅 acquis et la vente est propos茅e le 09/09/2025 suite 脿 l'exercice d'options sur actions 茅mises par la soci茅t茅, avec paiement en 别蝉辫猫肠别蝉. Le d茅clarant indique n'avoir vendu aucun titre au cours des trois derniers mois. Le formulaire contient la d茅claration standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables mat茅rielles non divulgu茅es et mentionne l'adoption d'un plan en vertu de la r猫gle 10b5-1, le cas 茅ch茅ant.
Alnylam Pharmaceuticals (ALNY) meldet den geplanten Verkauf von 18.000 Stammaktien 眉ber UBS Financial Services an der NASDAQ, mit einem gesamten Marktwert von $8.300.070,00 und 131.079.015 ausstehenden Aktien. Die Wertpapiere wurden erworben und sollen am 09.09.2025 durch Aus眉bung von Aktienoptionen des Emittenten verkauft werden, die Zahlung erfolgte in Bargeld. Der Einreicher berichtet, in den letzten drei Monaten keine Wertpapiere verkauft zu haben. Das Formular enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind, und verweist gegebenenfalls auf die Annahme eines Rule鈥�10b5鈥�1鈥慞lans.
FAQ
What does the ALNY Form 144 disclose about the proposed sale?
When were the shares acquired according to the ALNY Form 144?
Does the Form 144 report any sales of ALNY securities in the past three months?
Through which broker will the ALNY shares be sold?
Does the filing indicate the seller relied on a Rule 10b5-1 plan?
